Table 2.
Associations of long-term statin treatment with neuroimaging biomarkers of aging and dementia
| Statin-Untreateda (0–3 months) N=604 |
Statin-Treateda (≥5 years) N=556 |
p-value | Cohen’s dd | |
|---|---|---|---|---|
| PiB PET SUVRb,c | 1.62 (0.46) | 1.65 (0.45) | 0.95 | 0 |
| Tau PET SUVRb [395,355] | 1.22 (0.13) | 1.24 (0.15) | 0.54 | 0.06 |
| FDG PET SUVR [89,92] | 1.52 (0.16) | 1.49 (0.16) | 0.33 | 0.06 |
| MRI Cortical Thickness [17,29] | 2.64 (0.16) | 2.61 (0.16) | 0.21 | 0.08 |
| WMH Percentageb [344,331] | 4.02 (3.69) | 4.50 (3.98) | 0.83 | 0.02 |
| FA Corpus Callosum Body [106,109] | 0.579 (0.049) | 0.571 (0.049) | 0.30 | 0.07 |
| FA Corpus Callosum Genu [106,109] | 0.581 (0.051) | 0.569 (0.054) | 0.035 | 0.14 |
a
Values are displayed as unadjusted mean (standard deviation)
b
Phenotypes were log-transformed for association testing
c
Brackets indicate the number of subjects with missing data, ordered as [statin-untreated, statin-treated]. When no brackets are listed, this indicates that complete data was obtained for that variable.
d
Effect sizes are adjusted for age and sex